Literature DB >> 22406983

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.

Timothy S Fisher1, Cris Kamperschroer, Theodore Oliphant, Victoria A Love, Paul D Lira, Regis Doyonnas, Simon Bergqvist, Sangita M Baxi, Allison Rohner, Amy C Shen, Chunli Huang, Sharon A Sokolowski, Leslie L Sharp.   

Abstract

4-1BB (CD137, TNFRSF9) is a costimulatory receptor expressed on several subsets of activated immune cells. Numerous studies of mouse and human T cells indicate that 4-1BB promotes cellular proliferation, survival, and cytokine production. 4-1BB agonist mAbs have demonstrated efficacy in prophylactic and therapeutic settings in both monotherapy and combination therapy tumor models and have established durable anti-tumor protective T-cell memory responses. PF-05082566 is a fully human IgG2 that binds to the extracellular domain of human 4-1BB with high affinity and specificity. In preclinical studies, this agonist antibody demonstrated its ability to activate NF-κB and induce downstream cytokine production, promote leukocyte proliferation, and inhibit tumor growth in a human PBMC xenograft tumor model. The mechanism of action and robust anti-tumor efficacy of PF-05082566 support its clinical development for the treatment of a broad spectrum of human malignancies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406983     DOI: 10.1007/s00262-012-1237-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  53 in total

1.  Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Authors:  Natalie J Miller; Shailender Bhatia; Upendra Parvathaneni; Jayasri G Iyer; Paul Nghiem
Journal:  Curr Treat Options Oncol       Date:  2013-06

Review 2.  Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.

Authors:  Ricardo L B Costa; Brian J Czerniecki
Journal:  NPJ Breast Cancer       Date:  2020-03-12

Review 3.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

4.  Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.

Authors:  Aruna Bitra; Tzanko Doukov; Michael Croft; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

Review 5.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 6.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

Review 7.  Mouse models in oncoimmunology.

Authors:  Laurence Zitvogel; Jonathan M Pitt; Romain Daillère; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

8.  Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.

Authors:  Olga K Afanasiev; Lola Yelistratova; Natalie Miller; Kotaro Nagase; Kelly Paulson; Jayasri G Iyer; Dafina Ibrani; David M Koelle; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2013-08-06       Impact factor: 12.531

9.  Agonist antibodies to TNFR molecules that costimulate T and NK cells.

Authors:  Ignacio Melero; Daniel Hirschhorn-Cymerman; Aizea Morales-Kastresana; Miguel F Sanmamed; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 10.  Milestones in the staging, classification, and biology of Merkel cell carcinoma.

Authors:  Ata S Moshiri; Paul Nghiem
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.